Prolactin and alteration of fertility
Authors:
M. Štelcl 1; P. Vrublovský 2; Š. Machač 2
Authors‘ workplace:
Reprogenesis, Brno, vedoucí lékař MUDr. M. Štelcl
1; IVF Clinic, Olomouc, vedoucí lékař MUDr. Š. Machač, Ph. D.
2
Published in:
Ceska Gynekol 2018; 83(3): 232-235
Overview
Aim:
Physiology and pathology of prolactin production, clinical consequences.
Design:
Review.
Setting:
Reprogenesis International, Brno.
Methods:
Study of current literature.
Conclusion:
In article is discussed physiology and pathology of prolactin production, influence of hyperprolactinaemia to ovarian function – anovulation, irregularities of cycle, amenorrhea. Separately is discussed problem of microprolactinoma and prolactinoma. Review of current therapeutic possibilities.
Keywords:
prolactin, hyperprolactinaemia, microprolactinoma, prolactinoma
Sources
1. Casanueva, FF., Mark, E., Molitch, ME., et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol, 2006, 65, p. 265–273.
2. Čedíkova, M., Babuška, V., Rajdl, D., et al. Srovnaní hladin prolaktinu, fT3 a fT4 ve folikulární tekutině žen s poruchou plodnosti a zdravých plodných dárkyň oocytů. Čes Gynek, 2012, 5, s. 471–476.
3. Freeman, ME., et al. Prolactin: structure, function, and regulation of secretion, Physiol Rev, 2000 80, 4, p. 1523–631.
4. Ganong, WF., et al. Přehled lékařské fyziologie. Praha, Galén, 1995, s. 356–358
5. Ježková, J., Hána, V., Kršek, M., Weiss, V., et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Ednocrinol, 2009, 70, 5, p. 732–741.
6. Jones, J., Bashir, T., Olney, J., et al. Cabergoline treatment for a large macroprolactinoma throughout pregnancy. J Obstet Gynecol, 1997, 17, p. 375–376.
7. Klibanski, A., Biller, B., Rosenthal, M., et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab, 1988, 67, p. 124–130.
8. Marek, J. Základy gynekologické endokrinologie. Praha, Grada, 2002, s. 137–150.
9. Molitch, ME. Medication-induced hyperprolactinaemia. Mayo Clinic Proceedings, 2005, 80, p. 1050–1057.
10. Molitch, ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary, 2002, 5, p. 55–65.
11. Schlechte, JA. Clinical practice. Prolactinoma. New Engl J Med, 2003, 349, p. 2035–2041.
12. Stalldecker, G., et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary, 2010, 13, 4, p. 345–350.
13. Verhelst, J., Abs, R. Hyperprolactinaemia: pathophysiology and management. Treat Endocrinol, 2003, 2, p. 23–32.
14. Webster, J., Pisciteli, G., Polli, A., et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New Engl J Med, 1994, 6, p. 904–909
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2018 Issue 3
Most read in this issue
- Prolactin and alteration of fertility
- Does EmbryoGlue transfer medium affect embryo transfer success rate?
- Vaccination against HPV and view of new possibilities
- Planned home births in the Czech Republic, 2018